• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIANG Xinyan, DU Shuang, DING Yang, ZHOU Jianping. Application and development of liposome injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 383-393. DOI: 10.11665/j.issn.1000-5048.20200402
Citation: XIANG Xinyan, DU Shuang, DING Yang, ZHOU Jianping. Application and development of liposome injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 383-393. DOI: 10.11665/j.issn.1000-5048.20200402
shu

Application and development of liposome injection

  • 1.

    Department of Pharmaceutics, School of Pharmacy， China Pharmaceutical University， Nanjing 211198

  • 2.

    Nanjing Sanhome Pharmaceutical Co.， Ltd.， Nanjing 211135, China

More Information
  • Received Date: April 19, 2020
    Graphical Abstract
    • Abstract
  • Liposome injection is one of the most successful special injections that use nanotechnology to enhance drug efficacy and reduce accompanied toxicity. New liposomes with special structures and functions have emerged since the first liposome injection containing doxorubicin was marketed. This review summarized the principles and research progress of Stealth liposome technology and cationic liposome technology, analyzed the structural and functional characteristics and clinical application advantages of liposome products that have been marketed from the perspective of pharmacology, introduced current research hotspots of new liposomes, and analyzed the current regulatory status of liposome injection at home and abroad, thereby providing theoretical reference for the research and development（R&D）, clinical translation and supervision of liposome injection.
    • FullText(HTML)
    • References (43)
  • [1]
    D'Mello SR, Cruz CN, Chen ML, et al. The evolving landscape of drug products containing nanomaterials in the United States [J]. Nat Nanotechnol, 2017, 12(6):523-529.
    [2]
    Lee W, Im HJ. Theranostics based on liposome:looking back and forward [J]. Nucl Med Mol Imaging, 2019, 53(4):242-246.
    [3]
    Fan Y, Zhang Q. Development of liposomal formulations:from concept to clinical investigations [J]. Asian J Pharm Sci, 2013, 8(2):81-87.
    [4]
    Schmitt CJ, Dietrich S, Ho AD, et al. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors [J]. Ann Hematol, 2012, 91(3):391-397.
    [5]
    Arantseva D, Vodovozova E. Platinum-based antitumor drugs and their liposomal formulations in clinical trials [J]. Russ J Bioorg Chem, 2018, 44(6):619-630.
    [6]
    Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use:an updated review [J]. Pharmaceutics, 2017, 9(2):12.
    [7]
    Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes:immunological responses [J]. Sci Technol Adv Mater, 2019, 20(1):710-724.
    [8]
    Lila ASA, Uehara Y, Ishida T, et al. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery [J]. Eur J Pharm Sci, 2014, 103(2):557-566.
    [9]
    Mima Y, Lila ASA, Shimizu T, et al. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity [J]. J Control Release, 2017, 250:20-26.
    [10]
    Lila ASA, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon:clinical challenge and approaches to manage [J]. J Control Release, 2013, 172(1):38-47.
    [11]
    Mészáros T, Csincsi áI, Uzonyi B, et al. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro [J]. Nanomed Nanotechnol, 2016, 12(4):1023-1031.
    [12]
    Rietwyk S, Peer D. Next-generation lipids in RNA interference therapeutics [J]. ACS Nano, 2017, 11(8):7572-7586.
    [13]
    Barba AA, Bochicchio S, Dalmoro A, et al. Lipid delivery systems for nucleic-acid-based drugs:from production to clinical applications [J]. Pharmaceutics, 2019, 11(8):360.
    [14]
    Chen Z, Zhang T, Wu B, et al. Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes [J]. Int J Nanomed, 2016, 11:991-1002.
    [15]
    Wang Y, Gao F, Jiang X, et al. Co-delivery of gemcitabine and Mcl-1 SiRNA via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer [J]. J Biomed Nanotechnol, 2019, 15(5):966-978.
    [16]
    Jabir NR, Anwar K, Firoz CK, et al. An overview on the current status of cancer nanomedicines [J]. Curr Med Res Opin, 2018, 34(5):911-921.
    [17]
    Kapoor M, Lee SL, Tyner KM. Liposomal drug product development and quality:current US experience and perspective [J]. AAPS J, 2017, 19(3):1-10.
    [18]
    He H, Yuan D, Wu Y, et al. Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs [J]. Pharmaceutics, 2019, 11(3):110.
    [19]
    Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, et al. Nanomedicine review:clinical developments in liposomal applications [J]. Cancer Nanotechnol, 2019, 10(1):11.
    [20]
    Harrison TS, Lyseng-Williamson KA. Vincristine sulfate liposome injection [J]. BioDrugs, 2013, 27(1):69-74.
    [21]
    Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer[J]. Cancer Chemother Pharmacol, 2011, 68(4):945-950.
    [22]
    Franze S, Selmin F, Samaritani E, et al. Lyophilization of liposomal formulations:still necessary, still challenging [J]. Pharmaceutics, 2018, 10(3):139.
    [23]
    Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J]. Nat Nanotechnol, 2019, 14(12):1084-1087.
    [24]
    Gazzano E, Rolando B, Chegaev K, et al. Folate-targeted liposomal nitrooxy-doxorubicin:an effective tool against P-glycoprotein-positive and folate receptor-positive tumors [J]. J Control Release, 2018, 270:37-52.
    [25]
    Zheng C, Ma C, Bai E, et al. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma [J]. Int J Clin Exp Med, 2015, 8(2):1658-1668.
    [26]
    Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery [J]. Front Pharmacol, 2015, 6:286.
    [27]
    Eloy JO, Petrilli R, Trevizan LNF, et al. Immunoliposomes:a review on functionalization strategies and targets for drug delivery [J]. Colloids Surf, B, 2017, 159:454-467.
    [28]
    Arabi L, Badiee A, Mosaffa F, et al. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin [J]. J Control Release, 2015, 220:275-286.
    [29]
    Espelin CW, Leonard SC, Geretti E, et al. Dual HER2 targeting with trastuzumab and liposomal encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer [J]. Cancer Res, 2016, 76(6):1517-1527.
    [30]
    Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology:state of the art and future perspectives [J]. J Control Release, 2018, 275:162-176.
    [31]
    Munster P, Krop IE, LoRusso P, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer:a phase 1 dose-escalation study [J]. Br J Cancer, 2018, 119(9):1086-1093.
    [32]
    Dou Y, Hynynen K, Allen C. To heat or not to heat:Challenges with clinical translation of thermosensitive liposomes [J]. J Control Release, 2017, 249:63-73.
    [33]
    Dicheva BM, ten Hagen TL, Schipper D, et al. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes [J]. J Control Release, 2014, 195:37-48.
    [34]
    Dou YN, Zheng J, Foltz WD, et al. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice [J]. J Control Release, 2014, 178:69-78.
    [35]
    Cheng Z, Yao K, Liu W, et al. Preparation and characterization of composite delivery system of paclitaxel-loaded temperature sensitive liposome and siRNA-loaded gold nanostar [J]. J China Pharm Univ（中国药科大学学报）, 2017, 48(4):445-452.
    [36]
    Alvarez‐Lorenzo C, Bromberg L, Concheiro A. Light‐sensitive intelligent drug delivery systems [J]. Photochem Photobiol, 2009, 85(4):848-860.
    [37]
    Miranda D, Lovell JF. Mechanisms of light‐induced liposome permeabilization [J]. Bioeng Transl Med, 2016, 1(3):267-276.
    [38]
    Luo D, Carter KA, Razi A, et al. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release [J]. Biomaterials, 2016, 75:193-202.
    [39]
    Xu H, Paxton JW, Wu Z. Enhanced pH-responsiveness, cellular trafficking, cytotoxicity and long-circulation of PEGylated liposomes with post-insertion technique using gemcitabine as a model drug [J]. Pharm Res, 2015, 32(7):2428-2438.
    [40]
    Kanamala M, Wilson WR, Yang M, et al. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery:a review [J]. Biomaterials, 2016, 85:152-167.
    [41]
    Zhao Y, Ren W, Zhong T, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity [J]. J Control Release, 2016, 222:56-66.
    [42]
    Chang M, Lu S, Zhang F, et al. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting [J]. Colloids Surf B, 2015, 129:175-182.
    [43]
    Chi Y, Yin X, Sun K, et al. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models [J]. J Control Release, 2017, 261:113-125.
    • Related Articles

  • Related Articles

    [1]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [2]BAI Yan, GUO Xinyao, QIN Qiliang, YAN Fang. Advances in research on mechanism of lactate dehydrogenase B in tumors[J]. Journal of China Pharmaceutical University, 2023, 54(2): 172-179. DOI: 10.11665/j.issn.1000-5048.20221112001
    [3]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [4]LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604
    [5]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [6]TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
    [7]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [8]DONG Hong, WU Ruixue, LIU Jiaqi, HUANG Qing, ZHOU Ya, HU Yiqiao. Advances in cancer photodynamic therapy[J]. Journal of China Pharmaceutical University, 2016, 47(4): 377-387. DOI: 10.11665/j.issn.1000-5048.20160401
    [9]SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.
    [10]YANG Li, YOU Qi-dong, YANG Yong, GUO Qing-long. Research advances in wogonin′s anti-tumor effects[J]. Journal of China Pharmaceutical University, 2009, 40(6): 576-579.

Catalog

    Get Citation
    PDF
    XML
    Article views (765) PDF downloads (1012) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365909

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return